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Dear Editor, 24 
Besides viruses, Mycoplasma pneumoniae and Chlamydia pneumoniae are common causes of 25 
community-acquired respiratory infections (CARI) in children. However, the causal agent of 26 
CARI remains unknown in many cases (1). Growing evidence suggests that Chlamydia-27 
related bacteria might have a pathogenic role in humans (2;3). Parachlamydia 28 
acanthamoebae and Protochlamydia naegleriophila have been detected in respiratory clinical 29 
samples (4;8) and their role in pneumonia is supported by in vitro studies and animal models 30 
(5). Rhabdochlamydia crassificans and Rhabdochlamydia porcellionis are intracellular 31 
pathogens of arthropods that also belong to the Chlamydiales order (6;7). A recent analysis 32 
suggests that Rhabdochlamydia spp. might affect morbidity and mortality in premature 33 
newborns (9), but their role in respiratory infections is unknown.  34 
Using three previously described real-time PCRs for the detection of P. acanthamoebae, P. 35 
naegleriophila and Rhabdochlamydia spp. (4;8;9), we aimed at assessing the prevalence and 36 
clinical significance of these bacteria in respiratory secretions of children. All available 37 
respiratory samples of children hospitalized between September 2004 and October 2006 with 38 
a diagnosis of CARI were retrospectively tested. Tracheobronchitis was defined by the 39 
presence of a new cough with at least one of the following signs (dyspnea, sputum, fever 40 
≥38°C) or a diagnosis of upper respiratory tract infection in the medical record. Pneumonia 41 
was considered in the presence of the above criteria and a new infiltrate on chest X-ray. As 42 
controls, we used respiratory samples of six children hospitalized during the same period 43 
without evidence of respiratory infection at time of sampling. Multiplex PCR assay for the 44 
detection of M. pneumoniae and C. pneumoniae was also performed using previously reported 45 
primers and probes (10).  46 
Twenty-nine patients were included (13 males, 16 females, median age: 5 years, range 3 47 
months-18 years). Most (90%) respiratory samples were nasopharyngeal secretions. Positive 48 
 3 
results for Chlamydia-related bacteria were obtained in 14 of 29 (48%) patients with CARI (2 49 
Parachlamydia, 11 Rhabdochlamydia, 1 both Para- and Rhabdochlamydia; Protochlamydia 50 
was not recovered) and 0/6 (0%) controls (p=0.06). Considering only cases of documented 51 
pneumonia (n=21), the rate of positive results was 52% (p=0.05 when compared to  controls). 52 
Clinical characteristics of the 14 patients with CARI and positive PCR results for 53 
Parachlamydia or Rhabdochlamydia spp. are summarized in the Table. An alternative causal 54 
agent of pneumonia was documented in two cases (M. pneumoniae and S. pneumoniae). Of 55 
the 12 patients without alternative etiology, 5 (42%) received a macrolide (to which 56 
Chlamydia-related bacteria are  susceptible). Interestingly, one patient who did not respond to 57 
initial beta-lactam monotherapy experienced a rapid improvement after start of 58 
clarithromycin. 59 
In conclusion, our study revealed a high prevalence of positive respiratory samples for 60 
Parachlamydia and Rhabdochlamydia spp.. A similar prevalence has been recently reported 61 
in premature neonates with respiratory distress syndrome (9), which suggests that airways 62 
colonization with these Chlamydia-related bacteria is common. Their pathogenic role in 63 
CARI  is supported by the fact that these bacteria were not recovered from respiratory 64 
samples of patients without evidence of respiratory infection and were the only possible 65 
causal agents of pneumonia in 12 of 14 cases.  66 
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Table. Clinical characteristics of respiratory infection in children with positive PCR results for Chlamydia-related bacteria 107 
Sex / age / 
underlying condition 
Type of pulmonary 
infection 
Other symptoms/signs Alternative etiology Supportive measures Treatment  
(response) 
Parachlamydia acanthamoebae 
F / 13 y / pinealoblastoma 
(neutropenia) 
Bilateral interstitial 
pneumonia  
Enterocolitis - - Meropenem, vancomycin (complete) 
M / 15 y / - Unilateral alveolar  
pneumonia 
Pleural effusion - - Amoxicillin/clavulanate, clarithromycin 
(complete) 
Rhabdochlamydia spp. 
F / 1 y / - Tracheobronchitis - S.pneumoniae 
(urinary antigen) 
Invasive ventilation Ceftriaxone, clarithromycin 
(complete) 
F / 2 y / - Unilateral alveolar  
pneumonia 
- - Oxygen supply Amoxicillin/clavulanate (complete) 
M / 2 y / - Unilateral alveolar  
pneumonia 
Rhinitis, pleural 
effusion 
- - Amoxicillin/clavulanate, clarithromycin 
 (complete) 
M / 2 y / cystic fibrosis Bilateral alveolar  
pneumonia 
- - - Amoxicillin/clavulanate  (complete) 
F / 3 y / - Bilateral alveolar 
pneumonia 
Rhinitis, pharyngitis, 
seizures 
M. pneumoniae  
(nose swab, PCR) 
- Clarithromycin (complete) 
M / 5 y / osteosarcoma 
(neutropenia) 
Unilateral alveolar 
pneumonia 
Rhinitis - - Ceftriaxone, amikacin  (complete) 
F / 9 y / methylmalonic 
acidemia 
Unilateral interstitial 
pneumonia 
- - - Amoxicillin/clavulanate  (no response) 
Then: clarithromycin (complete) 
F / 11 y / - Unilateral interstitial 
pneumonia 
Otitis media - Oxygen supply Clarithromycin (complete) 
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F / 14 y / cystic fibrosis Unilateral alveolar 
pneumonia 
- - Non-invasive 
mechanical ventilation 
Imipenem, ciprofloxacin (complete) 
F / 15 y / - Unilateral alveolar 
pneumonia 
Pleural effusion - Oxygen supply Amoxicillin/clavulanate, clarithromycin 
(complete) 
M / 17 y / - Tracheobronchitis 
 
- - - No treatment (complete) 
Parachlamydia acanthamoebae and Rhabdochlamydia spp. 
M / 1 month / - Tracheobronchitis 
 
Conjunctivitis - - No treatment (complete) 
 108 
y = year-old 109 
 110 
